Adjuvant EGFR-TKIs for Patients With Resected EGFR-Mutant Non-Small Cell Lung Cancer: A Meta-Analysis of 1,283 Patients

Adjuvant EGFR-TKIs for Patients With Resected EGFR-Mutant Non-Small Cell Lung Cancer: A Meta-Analysis of 1,283 Patients

BackgroundCisplatin-based chemotherapy was previously considered as the standard adjuvant therapy for improved overall survival (OS) in patients with non-small cell lung cancer (NSCLC) after surgery. However, the benefit was limited due to high risks of recurrence and adverse events. In the present...

Full description

Bibliographic Details
Main Authors: Rui-Lian Chen, Ling-Ling Sun, Yang Cao, Han-Rui Chen, Jing-Xu Zhou, Chu-Ying Gu, Ying Zhang, Si-Yu Wang, Wei Hou, Li-Zhu Lin
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-04-01
Series:Frontiers in Oncology
Subjects:
adjuvant EGFR-TKIs
non-small-cell lung cancer
EGFR mutation
resected
meta-analysis
brain recurrence
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.629394/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.629394/full

Similar Items